RecruitingPhase 2NCT05557877

Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer

Targeted Prevention of Postpartum-Related Breast Cancer

Sponsor

Mayo Clinic

Enrollment

100 participants

Start Date

Mar 9, 2023

Study Type

INTERVENTIONAL

Conditions

Breast Carcinoma

Summary

This phase II trial tests whether low-dose aspirin can affect markers of inflammation in postpartum (after childbirth) women planning to have a breast biopsy. Chronic inflammation may increase the risk of postpartum related breast cancer. Low-dose aspirin is a non-steroidal anti-inflammatory drug. Giving low-dose aspirin may affect markers of inflammation in blood and tissue and may prevent postpartum related breast cancer.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether low-dose aspirin can prevent a type of breast cancer that sometimes develops after pregnancy (called postpartum-related breast cancer). This type of breast cancer is rare but tends to be more aggressive, and the study aims to find a simple, safe prevention strategy. **You may be eligible if:** - You are between 18 and 45 years old - You have had a live birth within the last 10 years - You are pre-menopausal - You are willing to provide tissue, blood, and urine samples **You may NOT be eligible if:** - You have blood count levels that are too low (anemia or low platelets) - You are not able to take aspirin safely - You do not meet the age or birth history requirements Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.